You have just read some of the FACTS (Truth) about Electroconvulsive Therapy (ECT) as presented in the FDA Executive Summary.

You also read about some of the "Opinions" stated in the booklet: "What you should know about ELECTROCONVULSIVE THERAPY (ECT), published by Channing Bete Company, Inc. - 2009 Edition - Printed in U.S.A. - Channing Bete Company - One Community Place - South Deerfield, MA 01373. The booklet was obtained from Pine Rest Christian Mental Health Services, Grand Rapids, Michigan 49501 - ECT & TMS Clinic (616) 281-6341

For more conclusive reports on the "truth" about electroconvulsive therapy (ECT) see:
- www.ectresources.org/
- www.mindfreedom.org
- www.wildestcolts.com
- http://www.laurentenney.us/
- www.psychrights.org
- madinamerica.com
- fda.gov/medwatch
- http://www.professionalsagainstect.com

http://www.regulations.gov/#!documentDetail;D=FDA-2009-N-0392-0288
http://www.regulations.gov/#!documentDetail;D=FDA-2009-N-0392-0873
http://www.regulations.gov/#!docketBrowser;rpp=25;po=300;D=FDA-2009-N-0392

NOTE: The FDA Executive Summary was
Prepared for the
January 27-28, 2011 meeting of the Neurological Devices Advisory Panel
Meeting to Discuss the Classification of Electroconvulsive Therapy Devices (ECT)

After two long days of testimony before the FDA Neurological Devices Advisory Panel, the Panel's recommendation was: Maintain the Electroshock Device in Class III (3) (dangerous).

This recommendation calls for PMA's (pre-market analysis) by manufacturers of the electroshock device to prove Safety and Efficacy. The FDA can choose to accept or reject the recommendation by its Advisory Panel. The electroconvulsive therapy device remains in Class III (dangerous) until the FDA rules on reclassification.

NOTE: To read the FDA Executive Summary PDF in its entirety, Google:
ECT 515(i) Executive Summary or use the following Web address

Support of this brochure doesn't necessarily include the information/views shared on the web sites listed herein.

Support by:
- John Breeding, PhD - Austin, Texas
  http://www.wildestcolts.com
- Gerald D. Natzke D.O., F.A.A.E.M.
  Flint, Michigan
- James B. (Jim) Gottstein, Esq., Alaska
  http://psychrights.org

[UPDATE 09/22/2014]: Electroconvulsive Therapy is also used for the following medical conditions: Alzheimer's disease, Chronic pain, Dementia, Mental retardation, Parkinson's disease and Post-partum depression (psychosis)

This brochure is our investment in your well being!

FACTS

about

ELECTROCONVULSIVE THERAPY (ECT)

entering the

"Gray Zone"

For Educational Purposes Only

Brochure Designed With You in Mind

"Gray Matter" does matter!

Quote: "An Investment in Knowledge pays the best interest." - Benjamin Franklin -

Quote: "The goal of education is the advancement of knowledge and the dissemination of Truth!" - John F. Kennedy -
What many psychiatrists are saying about
Electroconvulsive Therapy

- IN BOLD CONTRAST TO -

FDA
ECT 515(r) Executive Summary
[Docket No. FDA-2009-M-0101]

[Note the following statement: There's an exception to every rule; while this brochure refers to the booklet distributed by Pine Rest of Grand Rapids, MI as one resource, not all psychiatrists are in agreement with the opinion presented in the booklet. The medical symbol with * The booklet states; confirms that's where the information was obtained. The ClipArt with * Fact: FDA Executive Summary; confirms the source as well. Exact words are identified with quotation marks.]

* The booklet states; "it's a Myth" that ECT causes permanent memory loss." It goes on to say; "Studies show that a permanent inability to form new memories is highly unlikely. Some difficulty remembering events surrounding the period of ECT is common, but most of these memories usually return weeks or months after ECT stops."

* The booklet states; "it's a Myth" that ECT causes pain. It goes on to say; "There is no scientific evidence that ECT causes pain."

* The booklet states; "it's a Myth" that ECT causes brain damage. It goes on to say; "There is no scientific evidence that ECT causes brain damage."

* FACT: FDA Executive Summary Draft - Required contents of manufacturer submissions included: indications for use, device description, device labeling, risks, alternative practices and procedures, summary of preclinical and clinical data, and a bibliography. Report from the Manufacturer Docket Submissions is as follows: "The two U.S. manufacturers of the electroconvulsive therapy (ECT) device, METCA and Somatics, reported the following potential risks: Prolonged seizures, Cardiac arrhythmias, complications of pre-existing medical conditions, Death, Brain Damage (including structural injury, brain cell injury), (Brain stem rupture or hippocampal damage), Cognitive adverse events such as Short-term confusion, Short-term memory loss, Long-term (persistent or permanent) memory loss, Risk of everyday or semantic memory loss, Skin burns, Electrical hazards (including risk of excessive dose administration)."

* FACT: FDA Executive Summary of January 2011 states that potentially significant adverse events associated with ECT include: physical trauma, fractures, cardiac ischemia, cardiac arrhythmias, prolonged apena (lack of oxygen) and death. Other adverse events are noted such as; Treatment-emergent Mania, Exacerbation of psychiatric symptoms and/or negative subjective reactions such as Headache, Muscle soreness (Pain), Nausea and Vomiting.

* FACT: FDA Executive Summary of January 2011 states that potentially significant adverse events associated with ECT include: physical trauma, fractures, cardiac ischemia, cardiac arrhythmias, prolonged apena (lack of oxygen) and death. Other adverse events are noted such as; Treatment-emergent Mania, Exacerbation of psychiatric symptoms and/or negative subjective reactions such as Headache, Muscle soreness (Pain), Nausea and Vomiting.

Are you being asked to consider undergoing the psychiatric procedure of electroshock, commonly referred to as electro-convulsive therapy, ECT? If so please consider the following information and educate yourself before signing an "informed consent" to treat with ECT. Ask questions, get answers!

This ClipArt indicates that the information you are reading was obtained from the FDA Executive Summary prepared for the Neurological Devices Panel meeting of January 27-28, 2011.

The medical symbol indicates the information was obtained from a booklet distributed by Pine Rest Christian Mental Health Services, Grand Rapids, Michigan.